AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04339972 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LIFUP
Description: The same as LIFUP but the device is not turned on and the subject does not receive any ultrasound.
Study NCT02580071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sheng-Yu-Tang
Description: Granulated formula will be prescribed by KO DA Pharmaceutical co., LTD (科達) composition of formula is as follows: Radix Rehmanniae Praeparata 4g Radix Paeoniae Alba 4g Radix Astragali 4g Radix Ginseng 4g Radix Angelice Sinensis 2g Rhizoma Chuanxiong 2g (for preperation method and concentration ratio's please refer to manufacturers information)~patients will be required to take 4.2gr, t.i.d (total of 12.6gr per day)
Study NCT04806425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: intralipid is given as a preconditioning drug during off bump coronary artery bypass grafting surgery to measure efficacy in decreasing post operative ischemia
Study NCT04806425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline is given in same volume to normal saline group over the same duration
Study NCT03793166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT03793166 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV
Study NCT03793166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03793166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03793166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03793166 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT03767374 — intervention group
Intervention type: PROCEDURE
Intervention: Anal swab sample
Description: Anal samples using swab at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
Study NCT02411591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.
Study NCT02638610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochet-Bonnet aesthesiometer
Description: The eyelid's sensation will be assessed at 6 points of the eyelid using the Cochet-Bonnet aesthesiometer (Luneau Ophtalmologie, Paris, France). Measurements will take place before surgery, and two weeks, three months and six months after surgery.~This instrument contains a 6 centimeters long, retractable, flexible monofilament. For any given length, when applied perpendicularly to a test surface, the filament will exert a precise pressure before visibly bending. The filament's length inversely corresponds to the pressure exerted by the aesthesiometer such that the shorter the filament length, the more pressure it exerts on the test surface.
Study NCT04058821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Novel MRI scan - 7 days post injury
Description: * A turbo spin-echo localiser (20 seconds)~* Single-shot echo planar diffusion tensor imaging (7 minutes)~* 3D constructive interference in steady state (CISS, 6 minutes)~* Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)
Study NCT03767374 — intervention group
Intervention type: PROCEDURE
Intervention: Fecal sample
Description: Fecal sample at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
Study NCT03793166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03793166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03793166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03793166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03793166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03698019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT04058821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Novel MRI scan - 14 days post injury
Description: * A turbo spin-echo localiser (20 seconds)~* Single-shot echo planar diffusion tensor imaging (7 minutes)~* 3D constructive interference in steady state (CISS, 6 minutes)~* Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)
Study NCT04058821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional MRI scan - 6 months post brachial plexus exploration
Description: * Continuous whole brain echo-planar imaging~* High-resolution T1-weighted imaging of the brain~* Bilateral magnetic resonance spectroscopy (12 minutes)
Study NCT04058821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional MRI scan - 12 months post brachial plexus exploration
Description: * Continuous whole brain echo-planar imaging~* High-resolution T1-weighted imaging of the brain~* Bilateral magnetic resonance spectroscopy (12 minutes)
Study NCT04276662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: 1 dose of 50 mg DS-3201b
Study NCT03044353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698 (CPHPC)
Description: 20mg/hour, IV (in the vein) for up to 72hours followed by 60mg three times daily subcutaneous injection for 11 days. Number of cycles: up to 6. Dose level and frequency adjusted according to renal function
Study NCT00670111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insignia Plus / Ultra (Guidant/Boston Scientific)
Description: Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.
Study NCT03348514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 30 mg/m^2
Description: CPX-POM
Study NCT03348514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 60 mg/m^2
Description: CPX-POM
Study NCT03348514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 120 mg/m^2
Description: CPX-POM
Study NCT03348514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 240 mg/m^2
Description: CPX-POM
Study NCT03348514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 360 mg/m^2
Description: CPX-POM
Study NCT03348514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 600 mg/m^2
Description: CPX-POM
Study NCT03348514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 900 mg/m^2
Description: CPX-POM
Study NCT03348514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM - 1200 mg/m^2
Description: CPX-POM
Study NCT01873950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Study NCT01873950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dofetilide
Study NCT01873950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Study NCT01873950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine sulfate
Study NCT01873950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03767374 — intervention group
Intervention type: OTHER
Intervention: Risk factor assessment
Description: Patients will be asked questions on risk factors associated with MDR/XDR colonization at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization
Study NCT02842632 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: theoretical test
Description: The theoretical test is a multiple choice test which consists of 50 questions with 1 point per question (max. 50 points). It will be done before the teaching, after the 2 teaching sessions and 3 Months after the study
Study NCT03398772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Health Coaching Program
Description: Comprehensive Health Coaching Program: included physical activity and motivational interviewing techniques, participants were encouraged to set goals with decision-making, self-management and self-monitor their progress, and received support from researcher.
Study NCT02631161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equia Forte
Description: Restoration of cavities with a Glasshybrid material (Equia Forte)
Study NCT02631161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtek Supreme XT/Clearfil SE Bond
Description: Restoration of cavities with a composite resin based material after placing an adhesive
Study NCT03147027 — intervention group
Intervention type: PROCEDURE
Intervention: VT ablation
Description: Substrate mapping for VT will be performed with the CARTO electroanatomical system.
Study NCT02842632 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: practical test
Description: The practical test is an evaluation of 11 basic perioperative TEE examination on the simulator (CAE Vimedix Simulator). Each view is evaluated on a scale of 0 to 10 according to predetermined criteria including image angle, overall clarity and visualization of 3 major anatomic structures pertinent to each view. Each view can receive a maximum score of 10 and each study a maximum of 109 (ME asc. aortic LAX has only 2 main structures). It will be done after the first and second teaching session, and 3 Months after the study.
Study NCT01157130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Regimen
Description: Exercise instruction
Study NCT01960920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtered diesel exhaust
Description: Mask-filtered exposure to diesel exhaust
Study NCT01960920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filtered diesel exhaust
Description: Mask-filtered exposure to diesel exhaust
Study NCT01960920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unfiltered diesel exhaust
Description: Diesel Exhaust Inhalation
Study NCT01960920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unfiltered diesel exhaust
Description: Diesel Exhaust Inhalation
Study NCT01960920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clean air
Description: No pollution and no filter mask
Study NCT01960920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clean air
Description: No pollution and no filter mask
Study NCT02436005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phenacite
Description: Subjects will be randomized to wear the Phenacite contact lenses binocularly.
Study NCT02436005 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phenacite
Description: Subjects will be randomized to wear the Phenacite contact lenses binocularly.
Study NCT02436005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
Study NCT02436005 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
Study NCT02598063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil
Description: ADV will be administered orally at a dose of 10 mg QD for 72 weeks.
Study NCT02598063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.
Study NCT02598063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.
Study NCT02598063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a injection will be administered at a dose of 180 mcg QW for 48 weeks.
Study NCT03527485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 11UCB-J PET Scan
Description: 11UCB-J PET Scan
Study NCT03587493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BLOOD SAMPLE ANALYSIS
Description: Peripheral venous blood sampling just before lung transplantation, at day 15 and at post-transplantation M1 for lymphocyte phenotyping by cytometry
Study NCT01107093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDB-2914 (ulipristal acetate)
Description: single oral dose of 30 mg
Study NCT01107093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose
Study NCT04678856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study NCT04678856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study NCT00033917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indomethacin
Description: an anti-inflammatory drug
Study NCT00033917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline
Study NCT03004118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutridrink
Description: Liquid meal of 200ml
Study NCT03004118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutridrink
Description: Liquid meal of 200ml
Study NCT03004118 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: High resolution manometry probe
Description: Catheter inserted via the nose into the stomach to measure intragastric pressure.
Study NCT03004118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High resolution manometry probe
Description: Catheter inserted via the nose into the stomach to measure intragastric pressure.
Study NCT03004118 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: perfusion catheter
Description: Catheter inserted via the nose into the stomach to perfuse the nutridrink intragastricly.
Study NCT03004118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: perfusion catheter
Description: Catheter inserted via the nose into the stomach to perfuse the nutridrink intragastricly.
Study NCT03004118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 4 week oral intake (daily)
Study NCT03004118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursochol oral tablet
Description: 4 week oral intake (daily) (dose of 10.5mg/kg/day)
Study NCT03698019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT03698019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03698019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03004118 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Duodenal fluid aspiration catheter
Description: Catheter inserted via the nose into the duodenum to aspirate duodenal fluids for 2.5 hours.
Study NCT03004118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal fluid aspiration catheter
Description: Catheter inserted via the nose into the duodenum to aspirate duodenal fluids for 2.5 hours.
Study NCT03004118 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Duodenogastroscopy
Description: Catheter inserted via the mounth into the duodenum to take duodenal biopsies.
Study NCT03004118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenogastroscopy
Description: Catheter inserted via the mounth into the duodenum to take duodenal biopsies.
Study NCT03004118 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Description: Blood sample will be taken to measure liver enzyme serum levels and marker for bile acid synthesis.
Study NCT03004118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Blood sample will be taken to measure liver enzyme serum levels and marker for bile acid synthesis.
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination
Description: To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mini-Mental State Examination
Description: To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Administered Gerocognitive Examination
Description: To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Self-Administered Gerocognitive Examination
Description: To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale
Description: To be completed at the Screening Visit and at POD 90
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Geriatric Depression Scale
Description: To be completed at the Screening Visit and at POD 90
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index
Description: To be completed at the Screening Visit and at POD 90
Study NCT03698019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03698019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03698019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03698019 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study NCT03698019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT03044353 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2398852 (anti-SAP mAb)
Description: Up to 1200mg, IV divided over days 1 and 3. Number of cycles: up to 6. Dose level adjusted based on tolerability.
Study NCT04001764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The radial artery cannulation over 2 cm of the wrist
Description: The radial artery catheterization performed as short axis out-of-plane with USG over 2 cm of the wrist.
Study NCT04001764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The radial artery cannulation in the distal 3/4 area of the forearm
Description: The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
Study NCT04001764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The radial artery cannulation in the distal 1/2 area of the forearm
Description: The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
Study NCT05134389 — intervention group
Intervention type: PROCEDURE
Intervention: One Anastomosis Gastric Bypass
Description: Exposure to One Anastomosis Gastric Bypass
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Charlson Comorbidity Index
Description: To be completed at the Screening Visit and at POD 90
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Form 36 Health Survey
Description: To be completed at the Screening Visit
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Short Form 36 Health Survey
Description: To be completed at the Screening Visit
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Confusion Assessment Method
Description: To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Confusion Assessment Method
Description: To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memorial Delirium Assessment Scale
Description: To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Memorial Delirium Assessment Scale
Description: To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)